tag bristol-myers-squibb 
The Pharma Data
AUGUST 18, 2020
Bristol Myers Squibb has scooped up the sole rights to the interleukin-12 (IL-12) immunotherapy programme of Massachusetts-based biotech Dragonfly Therapeutics, handing over $475 million for the privilege.
pharmaphorum
JANUARY 11, 2021
That made things difficult for development partner Bristol-Myers Squibb , which inherited the drug previously known as bb2121 through its acquisition of Celgene late in 2019. million price tag. The FDA is now due to make a decision on ide-cel as a treatment for multiple myeloma in late March.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 25, 2022
It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK’s first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio’s CAR-T therapy Abecma (idecabtagene vicleucel) and J&J/Legend Biotech’s CAR-T Carvykti (ciltacabtagene autoleucel).
Pharmaceutical Technology
MAY 15, 2023
Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.
pharmaphorum
APRIL 5, 2022
The one-year survival rate with the drug was 73%, compared to 58% in a group receiving standard-of-care – off-label immune checkpoint inhibitors used for other forms of melanoma like Merck & Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Yervoy (ipilimumab) or chemotherapy with dacarbazine.
XTalks
AUGUST 19, 2022
Along with beti-cel, there is one being developed for sickle cell (approved in Europe as Skysona or eli-cel) and another being jointly developed with Bristol Myers Squibb for melanoma. Zynteglo’s hefty price tag of $2.8 Bluebird has a total of three gene therapies in its pipeline.
pharmaphorum
JULY 25, 2022
.” GSK’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) was the first BCMA-targeting drug to reach the market in 2020, and has since been joined by Carvykti as well as Bristol-Myers Squibb and bluebird bio rival CAR-T therapy Abecma (idecabtagene vicleucel).
Expert insights. Personalized for you.
52 
Let's personalize your content